Cutia Therapeutics

科笛集团

02487.HK

R&D-driven dermatology-focused biopharmaceutical company developing treatments for localized adipose accumulation, scalp and skin diseases, and topical anesthesia, with one core recombinant collagenase candidate and eight pipeline products; also distributes two commercialized products from overseas partners, primarily in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Distribution model
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Particular sales arrangements
• Key long-term agreements
• Negative operating cash flow
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Adverse change after the track record
• Non-recurring gains and losses
• Related-party transactions and balances
• Chapter 18A biotech